{"id":"W2954510583","doi":"10.1016/s1474-4422(19)30141-3","title":"Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Ipsen; Deutsches Zentrum für Neurodegenerative Erkrankungen; H. Lundbeck A/S; Deutsche Stiftung Neurologie; NOMIS Stiftung; Roche; Deutsche Forschungsgemeinschaft; Deutscher Akademischer Austauschdienst; AbbVie; European Commission; Novartis; ParkinsonFonds Deutschland; Bundesministerium für Bildung und Forschung; Deutsche Parkinson Vereinigung; European Parkinson’s Disease Association; Bischof Dr. Karl Golser Stiftung; Teva Pharmaceutical Industries; Damp Stiftung; UCB; Arthur Arnstein Stiftung; Horizon 2020; Actelion Pharmaceuticals; Biogen; Michael J. Fox Foundation for Parkinson's Research","keywords":"Placebo; Double blind; Medicine; Gallate; Randomized controlled trial; Atrophy; Epigallocatechin gallate; Internal medicine; Pharmacology; Alternative medicine; Pathology; Chemistry; Antioxidant","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002609836,0.002823483,0.006611646,0.0008331811,0.0007910813,0.00155314,0.001297396,0.004443004,0.008329245],"category_scores_gemma":[0.002986673,0.001289927,0.003847994,0.0006847248,0.002449204,0.001878615,0.0006743255,0.003843309,0.001458347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007743472,"about_ca_system_score_gemma":0.001059388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001211769,"about_ca_topic_score_gemma":0.00147737,"domain_scores_codex":[0.998917,0.0004956339,0.000102389,0.000254932,0.00008771801,0.0001422513],"domain_scores_gemma":[0.9985954,0.0004770746,0.0003203911,0.0001265004,0.0001217527,0.0003589268],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9939834,0.00120321,0.0001463846,0.000527079,0.000603956,0.00001968322,0.00001854275,0.00004833623,0.000789118,0.00003409884,0.00014103,0.002485113],"study_design_scores_gemma":[0.9736446,0.02459045,0.0006765074,0.00003405534,0.0005551098,0.00001216952,0.00001081106,0.00008933385,0.0001326197,0.0000694207,0.0001746575,0.00001016019],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9670788,0.01978962,0.001138996,0.001318633,0.001778376,0.004980592,0.001367927,0.0002053549,0.002341782],"genre_scores_gemma":[0.9792815,0.007460417,0.001302341,0.001500283,0.00120432,0.004230621,0.0009657356,0.00003892156,0.004015848],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008329245,"threshold_uncertainty_score":0.0278641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02532264812165638,"score_gpt":0.2696299688208813,"score_spread":0.2443073206992249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}